Young BA, diabetes and kidney disease in Veterans. Novartis data on file. Controlled Garber A, Effects of vildagliptin on glucose control in patients with type 2 diabetes insufficiently with a sulphonylurea -. Diabetes, Obesity and Metabolism 2008; 10:1326-1463.
Separately reinforced an analysis of pooled data from over 1,400 patients that Galvus in type 2 diabetic patients with mild to moderate renal tolerated. Decreased renal function is more common in patients with type 2 diabetes, with the prevalence of kidney disease by 20-40 percent. The analysis also confirmed there were no adverse changes in renal function after long-term treatment with Galvus. Similar efficacy was achieved in patients with mild renal impairment and those with normal renal function. Galvus is currently patients with moderate or patients with moderate or severe renal impairment in Europe. Continue reading